Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction
NCT07115056 · Campbell Clinic · PHASE4 · withdrawn · last registry update 2026-03-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficulty with study implement study related to staffing issue \& approvals.” | – | Registry record, Campbell Clinic |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: Henry Ford Health System, Tranexamic Acid (NCT03037515)
- 2026-10-26Results posted on the registry: Population Health Research Institute, Tranexamic Acid (NCT03954314)
- 2026-10-26Also stopped (terminated): Population Health Research Institute, Tranexamic Acid (NCT03954314)
- 2026-10-19Phase 3 first posted: Dave Bernholt, Tranexamic Acid + Placebo (NCT07880743)
- 2026-10-15Results posted on the registry: Oregon Health and Science University, Tranexamic acid (NCT06000423)
- 2026-09-23Phase 3 first posted: Tata Memorial Centre, Chlorophyllin, Sodium Copper Complex + Placebo (NCT07837713)
- 2026-09-17Phase 3 first posted: Western University, Canada, Tranexamic Acid (NCT07825350)
- 2026-08-27Phase 3 first posted: Fudan University, a drug against PLG (NCT07790354)
- 2026-08-25Phase 3 first posted: Fudan University, Early Angong Niuhuang Pill Treatment + Yiqi Huayu Jiedu Mixture (NCT07784569)
- 2026-07-29Phase 3 first posted: Prince of Wales Hospital, Shatin, Hong Kong, Sodium Bicarbonate (NaHCO3) + Warmed lignocaine (NCT07734740)
- 2026-07-23Also stopped (withdrawn): University of Minnesota, 1%Tranexamic acid with standard local + 3% TXA (NCT06345833)
- 2026-06-26Phase 3 first posted: Murdoch Childrens Research Institute, Tranexamic Acid (IV) + Placebo (NCT07672158)
- 2026-06-24Results posted on the registry: SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-24Also stopped (terminated): SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-11Phase 3 first posted: Assiut University, nebulized tranexamic acid + Intravenous Tranexamic Acid (NCT07641946)
- 2026-05-27Results posted on the registry: University of Alabama at Birmingham, TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION (NCT05474027)
- 2026-03-27Results posted on the registry: Universitas Indonesia, Tranexamic acid injection (NCT03540368)
- 2026-03-16Phase 3 first posted: Sultan Qaboos University, tranexamic acid (1 g diluted in 100 mL of 0.9% saline + Normal (0.9%) saline (NCT07474077)
- 2026-03-04Phase 3 first posted: Assiut University, Oral tranexamic acid (NCT07448415)
- 2026-02-24Results posted on the registry: Nikola Matejcic, Tranexamic Acid Injectable Product + Placebo (NCT05397652)
- 2026-02-20Phase 3 first posted: Allama Iqbal Medical College, Group A: Tranexamic acid + Group B: Vasopressin (NCT07423156)
- 2025-12-09Results posted on the registry: Sunnybrook Health Sciences Centre, Tranexamic acid (NCT05075200)
- 2025-11-26Results posted on the registry: University of Michigan, Tranexamic acid injection (NCT05441592)
- 2025-11-24Phase 3 first posted: St. Olavs Hospital, Tranexamic Acid (Cyklokapron) (NCT07245264)
- 2025-10-31Results posted on the registry: Nicoletta C Machin, Recombinant Von Willebrand factor + Tranexamic Acid Injection [Cyklokapron] (NCT04344860)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision